FAQ/Help |
Calendar |
Search |
Today's Posts |
03-10-2017, 10:01 PM | #1 | ||
|
|||
Member
|
Inhibikase Therapeutics, with funding from The Michael J. Fox Foundation, began pre-IND studies of the company's novel Abelson tyrosine kinase (c-Abl) inhibitors, IkT-148009, as a potential Parkinson's disease (PD) treatment. Inhibikase is also one of the three entities studying Nilotinib as a PD treatment.
IkT-148009, is a highly potent, first-in-class, small-molecule drug designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson's disease, with the goal of reversing disease progression. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to prevent and/or reverse the loss of dopamine-secreting neurons in the brain by restoring neuroprotective mechanisms. IkT-148009 is believed to be 50 times more brain penetrable than Nilotinib due to the small size of the molecule. Inhibikase Wins $433, MJFF Grant to Study c-Abl Inhibitors as Parkinson's Treatment | GEN |
||
Reply With Quote |
"Thanks for this!" says: | eds195 (03-10-2017), jeffreyn (03-10-2017), lab rat (03-11-2017), RLSmi (03-11-2017), soccertese (03-11-2017) |
03-11-2017, 05:02 AM | #2 | ||
|
|||
Member
|
Todd Sherer (MJFF) gave an update on c-Abl related matters a couple of days ago. He writes about the upcoming MJFF el al. trial, and also about the work of Inhibikase, and the work of Georgetown University:
Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies | Parkinson's Disease Something else which may be of interest is the MJFF grant record for the current phase (i.e. the planning phase) of the MJFF et al. nilotinib trial: Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease | Parkinson's Disease and here is the MJFF grant record for the Inhibikase project: Small Molecule Inhibitors of C-Abl for Parkinson's Disease Modification | Parkinson's Disease |
||
Reply With Quote |
03-11-2017, 09:55 AM | #3 | ||
|
|||
Member
|
[QUOTE=jeffreyn;1238496]Todd Sherer (MJFF) gave an update on c-Abl related matters a couple of days ago. He writes about the upcoming MJFF el al. trial, and also about the work of Inhibikase, and the work of Georgetown University:
Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies | Parkinson's Disease Something else which may be of interest is the MJFF grant record for the current phase (i.e. the planning phase) of the MJFF et al. nilotinib trial: Thanks Jeffrey. The only update I would have on the above is that the MJFF et al trial is more likely to begin around Sept. Originally, the hope was mid-year (July). I also wouldn't be surprised if it pushes back a little more from there. But, it will happen, which is what matters. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Pain-RX - Cox 2 Inhibitor | Vitamins, Nutrients, Herbs and Supplements | |||
Ace inhibitor? | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Powerful Fox Ad Puts Focus on Embryonic Stem Cell Research | Parkinson's Disease |